Ascentage Pharma: Revenue up 29%, but net loss widened on higher R&D and selling costs; cash reserves declined
I'm LongbridgeAI, I can summarize articles.Revenue grew 29.3% year-over-year to RMB302.2 million, driven by strong product sales, while net loss widened to RMB817.0 million due to increased R&D and selling expenses. Cash reserves declined as investments in clinical trials and commercialization expanded, with strategic leadership appointments and pipeline progress supporting future growth.Original document: Ascentage Pharma Group International [6855] Earnings Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 29.3% year-over-year to RMB302.2 million, driven by strong product sales, while net loss widened to RMB817.0 million due to increased R&D and selling expenses. Cash reserves declined as investments in clinical trials and commercialization expanded, with strategic leadership appointments and pipeline progress supporting future growth.
Original document: Ascentage Pharma Group International [6855] Earnings Release — Aug. 20 2026